Revvity (RVTY) Stock Looks Reasonable On Cash Flow Yet Rich On Earnings
Revvity stock has delivered a 34.1% decline over the past five years, yet the current Discounted Cash Flow (DCF) intrinsic value estimate points to the shares trading below that intrinsic value, while earnings-based multiples suggest the stock is on the expensive side.
- Over the past five years, Revvity has produced a total return that is down 34.1%, which puts extra focus on whether the recent share price level is now more about recovery optimism than long-term value creation.
- The launch of the SuperFlex prenatal screening system may support expectations for future cash flows, while the planned divestment of the China Immunodiagnostics unit introduces execution risk around how the business mix and profitability evolve.
- Revvity only passes 2 of 6 valuation checks, which means the broader set of metrics leans more toward the stock not being a clear bargain, even though the intrinsic value estimate suggests it is undervalued by 23.0%.
For investors, the debate is whether Revvity's current price reflects a genuine discount to intrinsic value or whether the richer earnings multiples and low overall value score are better guides to what the stock is worth today.
Is Revvity a Bargain on Cash Flow?
The Discounted Cash Flow (DCF) model looks at the cash Revvity can generate for shareholders in the future and adjusts it back to today’s dollars. Revvity currently produces last twelve month free cash flow of about $545.6 million, and the model assumes those cash flows continue to grow rather than shrink. On that basis, the 2 Stage Free Cash Flow to Equity model arrives at an estimated intrinsic value of about $153 per share.
Compared with the current share price, this points to the stock trading at roughly a 23.0% discount, which suggests Revvity screens as undervalued on cash flow alone. The recent launch of the SuperFlex prenatal screening system provides a concrete new product stream, yet the market price still sits below the level implied by the cash flow projections.
On this Discounted Cash Flow view, Revvity stock currently looks undervalued relative to the cash it is expected to generate.
Our Discounted Cash Flow (DCF) analysis suggests Revvity is undervalued by 23.0%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.
Has Revvity Run Too Far on Earnings?
The P/E ratio suits Revvity because earnings are a key yardstick for mature, cash-generative healthcare businesses. Revvity currently trades on a P/E of about 55.4x, compared with a Life Sciences industry average of 37.3x and a peer average of 50.5x. That means you are paying a higher price for each dollar of Revvity’s earnings than for many sector alternatives.
A tailored fair P/E for Revvity is estimated at 27.5x, which is roughly half of where the stock trades today. This gap suggests the current market price builds in a richer earnings outlook and risk profile than the fair multiple implies. Even with products like the SuperFlex prenatal screening system in the mix, the earnings multiple already prices in a strong narrative and leaves less room for disappointment on future results.
On the P/E yardstick, Revvity stock currently screens as overvalued compared with both its tailored fair multiple and key industry benchmarks.
See what the numbers say about this price — find out in our valuation breakdown.
The Revvity Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the Revvity valuation puzzle leaves off and explain which paths for growth, margins and earnings would need to occur for the stock to be worth meaningfully more or less than it is today on the market. Each narrative links its number to a clear view of how Revvity's growth, profitability and risks could change over time, which you can revisit as fresh information and results come through. These narratives are available on Simply Wall St's Community page.
Community views on Revvity sit far apart, with one camp seeing improving earnings power and another focused on policy and valuation risk.
Bull case: roughly fairly valued
"Accelerating adoption of Revvity's high-growth software solutions (30%+ organic growth in Signals, record orders, high ARR and net retention), driven by pharma/biotech spending on digital transformation, supports sustained revenue growth and recurring, higher-margin streams..."
Read the full Bull Case to see why Revvity could be undervalued
Bear case: 31% overvalued
"Accelerating regulatory and reimbursement shifts in China, such as the DRG (diagnosis-related groups) debundling policy, are causing a sustained, high-teen percentage decline in Revvity's high-margin immunodiagnostics business in the region, which is expected to reduce total company organic revenue growth and operating margins in the near and medium term..."
Read the full Bear Case to see why Revvity could be overvalued
Do you think there's more to the story for Revvity? Head over to our Community to see what others are saying!
The Bottom Line
Revvity looks undervalued on a Discounted Cash Flow (DCF) view, with the intrinsic value estimate sitting above the current share price, yet the earnings multiples still point to an overvalued stock compared with peers and its own fair ratio. The low overall value score suggests investors should treat the DCF discount as only one piece of the puzzle, not a clear green light. The real swing factor from here is whether Revvity can deliver the cash flows and margins implied in the intrinsic value estimate without stretching its earnings multiple even further.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com